Panacea Biotec’s Dengue Vaccine Progress Analyzed
Panacea Biotec’s stock price jumped significantly, rising 9.3% to ₹418.35 per share. This jump happened because the company announced that they finished enrolling people in a major test of their new dengue vaccine, DengiALL. This vaccine is designed to protect against all four types of the dengue virus, making it a really important development for public health.
Key Points
- DengiALL: A single-shot vaccine protecting against all 4 dengue strains.
- 10,335 participants enrolled in a two-year clinical trial.
- Vaccine uses weakened virus to train the immune system.
- India’s first indigenous single-shot dengue vaccine candidate.
- Expected market launch by 2027, after successful clinical trials.
- Company history dating back to 2006, with US NIH collaboration.
DengiALL works by using weakened versions of the dengue virus. It’s like a training exercise for the body’s defense system. This “all-in-one” approach is super important because getting sick with one type of dengue can make it much worse if you get infected with another.
The company recruited 10,335 people to take part in the study. They’ll be watched for two years to see how well the vaccine works and how well it builds immunity. Panacea Biotec hopes to get the vaccine approved for use in India by 2027.
The development of DengiALL started way back in 2006, with help from scientists in the United States. They’ve already done smaller tests (Phase I and II) and they’ve been working closely with the Indian Council of Medical Research (ICMR) on the bigger trial.
The trial is taking place at 19 different locations across India, involving a large group of people. This research is a key step towards having a readily available vaccine to combat dengue fever.
“A successful vaccine against dengue promises to significantly reduce the burden of this widespread disease.”
